Bachem brings peptide and small molecule generic APIs to DCAT
Bubendorf, Switzerland: – Peptide technology specialist Bachem AG will be bringing its latest generics active pharmaceutical ingredients (APIs) and innovative selective glycosylation service to North America’s high-prestige DCAT Week.
Bachem Group increased its sales by about 15% in the first half of 2015 and with the acquisition of the American Peptide Company (APC) in early 2015, Bachem strengthens its expertise and expands its manufacturing capabilities. The acquisition as well as the very good results expected for 2015 further enhancing the global leadership of Bachem in peptides.
The company will use DCAT to present opportunities to harness its peptide and small molecule generic APIs and custom manufacturing capabilities. These include its selective chemical glycosylation service, using Bachem production expertise to scale up a proprietary technology developed by GlyTech, Inc. of Japan, now applicable in large-scale production across a wide range of peptides.
Innovative APIs
Bachem will be represented at DCAT by its US subsidiary, Bachem USA of Torrance, CA, and its headquarters Bachem AG, Bubendorf, Switzerland who will be in Suite 40M at New York’s famous Waldorf Astoria hotel.
In a recent X-Talks webinar, presented by GlyTech board adviser, Dr. Michael F. Haller, Ph.D., insights on how the selective glycosylation can improve physicochemical properties of peptides were provided.
Bachem’s CMO, Dr. José de Chastonay, will lead the team at DCAT and will also participate the special Dinner Table for invited partners at the final evening Annual Dinner.
Pioneering Partner for Peptides
The team will be busy throughout DCAT week, using the event’s unique format and networking opportunities to discuss potential collaborations which can harness Bachem’s outstanding knowledge of peptide and carbohydrate chemistry. Their mission ‘Pioneering Partner for Peptides’ describes an organization that actively supports clients through all phases of active ingredient development and commercialization.
Bachem will also present its other services such as its award-winning single glycosylation process that has enabled a production scalable chemical synthesis of Interferon β-1a, along with custom manufacturing, synthetic organic chemistry, generic peptidic and small molecule APIs and sterile dosage forms and products like Clinalfa® for use in approved clinical studies.
Scale up capabilities
These and other services feature in the latest Bachem video, now viewable online.
“We look forward to returning to DCAT Week in New York, which is a great place for us to meet our core audience of pharmaceutical and chemical sourcing professionals, manufacturers and distributors,” said Martina Diekmann, Bachem’s Head of Global Marketing.
”We will be able to show our capabilities to produce peptide and small molecule generic APIs from gram to hundreds of kilogram scale under cGMP conditions in state of the art facilities and with full documentation to comply with FDA and local regulatory requirements,“ Dr. Diekmann added.
About Bachem
The Bachem Group is the world’s only full service provider of peptides and provides a full range of other services to the pharma and biotech industries.
Under its banner Pioneering Partner for Peptides, Bachem specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients (APIs). A comprehensive catalog of biochemicals and exclusive custom syntheses for research labs complete its service portfolio.
Headquartered in Switzerland with subsidiaries in Germany, the UK, and the USA, the group specializes in process development and the manufacture of peptides and complex organic molecules as APIs as well as innovative biochemicals for research.
Bachem prioritizes continuous investment in R&D on chemistries and technologies as crucial for future success. Its ever-increasing knowledge of complex proteins and peptides derives from ongoing research in proteomics, as well as progress in mass spectrometry, synthesis and ligation technologies, complemented by collaboration with external research institutions.
Bachem has six production sites in the U.S. and in Europe along with research level production and full cGMP manufacturing facilities on both continents. These provide capacity to produce APIs, key intermediates, small molecule generics and new chemical entities (NCEs) at preclinical, clinical and production scales.About DCAT Week
The Drug, Chemical & Associated Technologies Association (DCAT), founded in 1890, has become North America’s premier business development association for companies that manufacture, distribute or provide services to the pharmaceutical and chemical industries.
DCAT represents the entire spectrum of the pharmaceutical industry—from pharmaceutical, API, and excipient sales and manufacturing to distribution, support technologies and packaging products and services.
Attended by thousands of industry professionals, DCAT Week® and the DCAT Annual Dinner, held each March in New York City, are considered one of the pharma industry’s premier events.
DCAT Week 2016 will take place over four days from March 14 to March 17 and will once again be centered on New York’s landmark Waldorf Astoria Hotel.
Unlike most industry exhibitions, DCAT Week is not a trade show with stands or booths. Instead, DCAT members hold high-level strategic meetings with customers and suppliers in a block of business meeting suites across a range of prestige NYC hotels, including the New York Palace, Lexington and Hyatt 48 Lex.
DCAT members make their own appointments, some scheduling upwards of 100 meetings during the week.
Press Release | Bachem AG
JANUARY 25, 2016Source: http://www.pharmaceutical-networking.com/
